Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Forteo
Forteo (teriparatide) is an anabolic agent used to treat osteoporosis in postmenopausal women and men at high risk for fracture. It is a synthetic form of parathyroid hormone (PTH), a naturally occurring hormone that regulates calcium and phosphate metabolism in bones. Forteo stimulates new bone formation, leading to increased bone mineral density and reduced fracture risk. However, it is important to note that Forteo carries a risk of osteosarcoma (bone cancer) and is generally limited to a two-year duration of use.
Forteo is used to treat osteoporosis in postmenopausal women and men at high risk for fracture.
Forteo may increase the risk of osteosarcoma (bone cancer).
Outcome:
Increased risk of digoxin toxicity
Mechanism:
Altered calcium levels
Outcome:
Reduced efficacy of teriparatide
Mechanism:
Inhibition of bone formation
Outcome:
Reduced absorption of teriparatide
Mechanism:
Binding to teriparatide
Most likely new formulation: sustained-release teriparatide (Year: 2026, 70% confidence)
Based on current usage patterns and clinical trial data, Forteo is expected to maintain its market share for the treatment of osteoporosis in high-risk patients.
Anabolic Agent, Bone Formation Regulator
Peptide Hormone